Texas Dairy Worker with Bird Flu Had Pinkeye, No Respiratory Symptoms
A new case report sheds light on the first documented transmission of bird flu from cow to human.
Tag: antiviral
All
Latest
All
Latest
FDA Grants Fast Track Designation to COVID-19 Oral Antiviral
The drug recently received emergency regulatory approval from the Ministry of Health, Labour, and Welfare of Japan for the treatment of SARS-CoV-2 infection.
All
Latest
Merck to License COVID-19 Antiviral to Drugmakers in Other Companies
Merck has entered into a voluntary licensing agreement to allow the production of its investigational COVID-19 antiviral molnupiravir by drugmakers in 105 low- and middle-income countries.
Remdesivir Has “Clear-cut” Benefits for COVID-19
The investigational antiviral remdesivir “has a clear-cut, positive effect in diminishing the time to recovery” for patients infected with COVID-19, NIAID director Anthony Fauci says.
Read More
COVID-19: FDA Okays Antiviral Shipments from Strategic National Stockpile
An FDA EUA will allow shipments of hydroxychloroquine sulfate and chloroquine phosphate from the Strategic National Stockpile for COVID-19.
Read More
FDA to Fast-track Potential Coronavirus Antivirals
The US FDA will fast-track potential antiviral medications to treat coronavirus, President Donald Trump announced at a White House briefing Thursday.
Read More
Xofluza Expanded to High-risk Flu Patients
The US FDA has approved a supplemental New Drug Application for Xofluza to treat flu in patients 12 and older who are at high risk of developing flu-related complications.
Read More
Cidara Developing Investigational Flu Antiviral
Cidara Therapeutics has selected the antiviral conjugate (AVC) CB-012 as its first clinical development candidate from the company’s Cloudbreak influenza antiviral program.
Read MoreRoche’s Xofluza Shows Benefits for High-risk Flu Patients
Roche’s investigational single-dose antiviral Xofluza showed superior efficacy in speeding up improvement of flu symptoms in people at high risk of complications.
Read MoreNew FDA-approved Antiviral to Fight the Flu
The FDA has approved single-dose antiviral Xofluza for the treatment of acute uncomplicated influenza in patients 12 years of age and older who have been symptomatic for no more than 48 hours.
Read More
FDA Fast Tracks RSV Antiviral BTA585
Biota Pharmaceuticals has been granted Fast Track designation from the FDA for its antiviral compound intended for the treatment of RSV.
Read MoreBiota Commences Dosing in Phase 2b Study of Rhinovirus Antiviral
Biota Pharmaceuticals Inc has commenced dosing of patients in its Phase 2b SPIRITUS trial of vapendavir for the treatment of human rhinovirus (HRV).
Read More